Up­dat­ed: Cel­lares to pro­duce Ca­balet­ta’s au­toim­mune CAR-T can­di­date 

Cel­lares an­nounced a new proof-of-con­cept part­ner­ship with Ca­balet­ta Bio to man­u­fac­ture the biotech’s au­toim­mune CAR-T cell ther­a­py.

The goal of the pro­gram is to “test the Cel­lares sys­tem us­ing Ca­balet­ta’s process and prod­uct to as­sess the plat­form’s abil­i­ty to man­u­fac­ture CA­BA-201,” Ca­balet­ta’s CD19-CAR T can­di­date, ac­cord­ing to Ca­balet­ta chief busi­ness of­fi­cer Arun Das. The tri­als are eval­u­at­ing mul­ti­ple in­di­ca­tions: sys­temic lu­pus ery­the­mato­sus, myosi­tis, sys­temic scle­ro­sis and gen­er­al­ized myas­the­nia gravis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER